Lamotrigine is cost-effective for maintenance treatment of bipolar I disorder
Published in Managed Care Law Weekly, August 6th, 2006
Researchers in England conducted a study "to present an economic model and cost-effectiveness estimates for lamotrigine in maintenance treatment of bipolar I disorder (BD-I) using outcomes from the pivotal lamotrigine trials."
"The main comparator treatments in the pivotal trials were lithium and 'no maintenance' (acute-only) treatment. A comparison with olanzapine was included as an indirect analysis following publication of data during the course of our research. A Markov model was built around the three health states of euthymia, mania, and depression,"...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Managed Care Law Weekly
More Articles from Managed Care Law Weekly
- Diabetes Prevention
Diabetes Prevention Program cost sharing may give financial returns in long-term - Healthcare Coverage
Aetna introduces national Medicare retiree health plan for employers - Medicare
Adaptis brings Medicare Advantage educational sessions to California - Medicare
America's Health Insurance Plans raises concerns over new Government Accountability Office report
Reports from the United States add new data to benign prostatic hyperplasia research- Academy of Athens, Greece
Cell lines derived from amniotic fluid cells express neuronal dopaminergic progenitor phenotype - More from this issue of Managed Care Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
